P₀ Glycoprotein Overexpression Causes Congenital Hypomyelination of Peripheral Nerves

Lawrence Wrabetz,* Maria Laura Feltri,* Angelo Quattrini,* Daniele Imperiale,** Stefano Previtali,* Maurizio D'Antonio,* Rudolf Martini,† Xinghua Yin,‡ Bruce D. Trapp,*, Lei Zhou,§ Shing-Yan Chiu,¶ and Albee Messing**

*Department of Neurology and Department of Biological and Technological Research (DIBIT), San Raffaele Scientific Institute, 20132 Milano, Italy; †First Division of Neurology, University of Torino, 10126 Torino, Italy; ‡Department of Neurology, Section of Developmental Neurobiology, University of Wurzburg, Wurzburg, Germany; §Department of Neurosciences, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195; ¶Department of Physiology, School of Medicine, University of Wisconsin-Madison, Madison, Wisconsin 53706; and **Waisman Center and Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, Wisconsin 53705

Abstract. We show that normal peripheral nerve myelination depends on strict dosage of the most abundantly expressed myelin gene, myelin protein zero (Mpz). Transgenic mice containing extra copies of Mpz manifested a dose-dependent, dysmyelinating neuropathy, ranging from transient perinatal hypomyelination to arrested myelination and impaired sorting of axons by Schwann cells. Myelination was restored by breeding the transgene into the Mpz-null background, demonstrating that dysmyelination does not result from a structural alteration or Schwann cell-extrinsic effect of the transgenic P₀ glycoprotein. Mpz mRNA overexpression ranged from 30–700%, whereas an increased level of P₀ protein was detected only in nerves of low copy-number animals. Breeding experiments placed the threshold for dysmyelination between 30 and 80% Mpz overexpression. These data reveal new points in nerve development at which Schwann cells are susceptible to increased gene dosage, and suggest a novel basis for hereditary neuropathy.

Key words: axon sorting • myelin • neuropathy • Schwann cell • transgene

Introduction

The myelin sheath displays a unique molecular architecture that depends on precisely regulated protein synthesis and trafficking. First, myelinating glia, Schwann cells in peripheral nerve, and oligodendrocytes in brain and spinal cord, must solve a remarkable problem of quantity: to produce as much as three times their weight in proteins and lipids per day of myelination (Norton and Poduslo, 1973). Coordinate synthesis of myelin proteins is in part transcriptionally mediated, as high-level transcription of the genes encoding myelin-specific proteins is induced simultaneously during myelination (Stahl et al., 1990; Scherer et al., 1994; Wrabetz et al., 1998). Second, the trafficking of these mRNA s and proteins is carefully regulated. For example, in myelin-forming Schwann cells, P₀ glycoprotein (P₀) is synthesized in the RER, and trafficked via the Golgi apparatus specifically to the forming myelin sheath (D’Ursio et al., 1990; Trapp et al., 1995). In contrast, the mRNA encoding myelin basic protein (MBP) is trafficked to cytoplasmic spaces adjacent to the forming myelin sheath, where MBP is synthesized on free ribosomes and rapidly incorporated into myelin (Colman et al., 1982; Trapp et al., 1987; Griffiths et al., 1989).

It is not surprising, therefore, that both naturally occurring and induced mutations reveal the importance of precisely regulated gene dosage for normal myelination. For example, the gain or loss of only one allele of the proteo-
lipid protein gene (PLP), or peripheral myelin protein 22 kD gene (PMP22), produce central nervous system (CNS) myelinopathies or demyelinating peripheral neuropathies in human (for reviews see Suter and Snipes, 1995; Nave and Boesplug-Tanguy, 1996), and similar dosage alterations of PLP and Pmp22 in transgenic rodents model these diseases (P1p: Boison and Stoffel, 1994; Kagawa et al., 1994; Readhead et al., 1994; Klugmann et al., 1997; and Pmp22: A dikofer et al., 1995; M agayar et al., 1996; Sereda et al., 1996; H uxley et al., 1998). How altered PLP expression causes dysmyelination is unclear (for review see Werner et al., 1998), but overexpressed PMP22 arrives to the myelin sheath (V allat et al., 1996), possibly destabilizing its formation or maintenance. The observation that mutations in diverse myelin genes produce similar disease phenotypes implies that various myelin proteins interact in functional units. In keeping with this, physical interaction between PMP22 and P0 may reflect a need for stringent stoichiometry during protein trafficking to, and assembly of, the myelin sheath.

Precisely regulated, as overexpression of P0 causes a dose-dependent, dysmyelinating neuropathy manifested by remarkably delayed nerve development, including Schwann cells that are unable to segregate axons. Thus far, we have identified two possible pathogenetic mechanisms. First, increasing P0 overexpression disregulates the stoichiometric expression of other myelin genes. Second, P0 overexpression promotes inappropriate trafficking of P0 to Schwann cell surface membranes (Y in et al., 2000, this issue). These findings have implications for both coordinate expression and trafficking of myelin proteins in developing nerve, and for dosage dependent human neuropathies, such as CMT1A.

### Materials and Methods

#### Production of Transgenic Mice

Construction of the transgenic vector mP<sub>TOTA</sub> has been described previously (Feltri et al., 1999). Like mP<sub>TOTA</sub>, mP<sub>TOT</sub> contains the complete Mpz with 6 kb of promoter, all exons and introns, the natural polyadenylation site, and a polymorphic BglII site in exon 3 (amino acid sequence conserved) that is absent from the endogenous FVB/N Mpz alleles. In contrast to mP<sub>TOTA</sub>, the AgT start site of translation of P0 remains. For oocyte injection, the transgene monomer was excised from the vector using XhoI and NotI.

Transgenic mice were obtained by standard techniques (Brinster et al., 1985) using fertilized eggs obtained from the mating of FVB/N mice (Taconic). Breeding lines of animals were maintained by backcrosses to FVB/N mice (Taconic or Charles River). Ten founders were identified by Southern blot and PCR analysis of genomic DNA prepared from tail samples (Sambrook et al., 1989). We documented expression in eight founders or their progeny; these were further analyzed in this study. A 770-nucleotide (nt) BamHI-HindIII restriction fragment from intron 1 of Mpz was used to generate a probe for Southern blot analysis of genomic DNA digested with BglII (Fig. 1). A set of transgenic and FVB/N alleles were recognized identically by this probe. Copy numbers were determined by the quotient of the 2.8-kb divided by the 6.8-kb band intensity in Southern blot analysis. The PCR primer sequences were: 5'-CCACCACCTCTCATTGCAAC-3' and 5'-GGCGGATTGACCGTAATGGG-3', and amplified a 540-nt fragment. BglII digestion of the product revealed additional fragments of 300 and 240 nt in transgenic samples (data not shown). PCR conditions were: 94°C for 30 s, 57°C for 30 s, and 72°C for 60 s (25 cycles), followed by 10 min extension at 72°C, in a standard PCR reaction mix. The genetic designations of the three lines that have been maintained.

---

**Figure 1.** Southern blot analysis for transgene copy number. Southern blot analysis (B) revealed ten founders (F80), from which three lines were established (Tg80). A polymorphic BglII restriction site (B<sup>+</sup>) distinguishes the mP<sub>TOT</sub> transgene from the endogenous Mpz FVB/N alleles (A). Copy numbers (CN) were estimated by the ratio of the 2.8-6.8-kb signal intensities.
from this study are transgenic lines: 80.2, TgN(Mpz)22M; 80.3, TgN (Mpz)23M; and 80.4, TgN(Mpz)24M.

P2 heterozygous (+/−) null mice were backcrossed to FVB/N mice for five generations and identified by PCR or Southern blot analysis of genomic DNA prepared from tail samples. The PCR primer sequences were: 5'-TCAGTTCTTGTGCCCGCTCTC-3' (forward, common), 5'-GGCTCGAGGTGCTTCGTGTTTGC-3' (reverse, neo) and 5'-A CT TGTTCTTCTCGTGATTAAATCA-3' (reverse, wild-type P2), and amplified a 500-bp fragment from a wild-type allele and a 334-bp fragment from the null allele. Multiplex PCR conditions were 94°C for 60 s, 53°C for 180 s, and 72°C for 180 s (40 cycles), followed by 10 min extension at 72°C, in a standard PCR reaction mix.

Tg80.4 and P2null animals were crossed to generate breeders for the rescue experiments. Southern blot analysis as for Tg80 (above) distinguished genotypes of offspring (see Fig. 8).

Behavioral Analysis
Tremor was estimated visually on a + to +++ scale. Strength was measured in the forelimbs of adult mice using a Grip Strength Meter (Columbus Instruments). In brief, mice were tested five consecutive times over a span of about one min, recording peak force applied to the strain gauge (in g). The maximum value achieved in the five tests was taken as an indication of strength and used for further calculations. To account for possible weakness due to muscle atrophy rather than strictly neural conduction deficits, strength was expressed as a ratio of the maximal peak force over body weight. The investigator performing the tests was blinded to the genotype of each mouse. A's grip strength/weight declined slightly with age in normal controls, all reported measurements derive from littermates between postnatal day 90 (P90) and P110.

Electrophysiologic Analysis
Transgenic mice and control littermates at P42 were anesthetized by i.p. injection of avertin, and the sciatic nerves quickly excised and placed in a nerve chamber at a bath temperature of 20°C. Mice were killed by decapitation, and the sciatic nerves were exposed and continuously perfused with Ringer's solution at room temperature to eliminate insoluble material. The protein in supernatant was determined by BioRad protein assay according to the manufacturer's instructions.

Northern Blot Analysis
Total RNA was isolated from mouse sciatic nerves and from various tissues (see Northern blot analysis as described (Feltri et al., 1999). Northern blot analysis was performed using cDNAs from mouse P2, rat MBP, and rat glyceraldehyde-3-phosphate dehydrogenase (GAPDH) to generate probes.

Western Blot Analysis
Frozen sciatic nerves dissected from P28 transgenic and nontransgenic littermates were pulverized, sonicated in lysis buffer (95 mM NaCl, 25 mM Tris-HCl, pH 7.4, 10 mM EDTA, 2% SDS, and protease inhibitors), boiled for 5 min, and spun at 14,000 rpm in a microcentrifuge for 10 min at room temperature to eliminate insoluble material. The protein in supernatants was determined by BioRad protein assay according to the manufacturer's instructions.

Morphological Analysis

Hematoxylin and eosin, and ATPase isozyme (pH 4.6 or 9.4) staining of posterior compartment muscles of the leg was performed according to standard clinical laboratory protocols. ATPase (pH 9.4) staining confirmed the presence of angulated fibers and the absence of fiber type grouping (not shown).

Routine semi-thin section and electron microscopic analyses of nerve was performed as described (Quattrini et al., 1996). In most cases, nerves from three to five animals were evaluated at each time point for each line of Tg80. When only founders were available, both sciatic as well as femoral nerves were evaluated. To account for variable genetic background in rescue experiments (performed in FVB/N N(2–5)F1 background), three to five animals of each genotype were evaluated by four investigators blinded to the genotype. Each genotype produced a highly reproducible phenotype.

Quantitation of myelinated fibers in developing motor (quadriceps) versus sensory (saphenous) branches of femoral nerve was performed as described (Frei et al., 1999).

The proportion of myelinated fibers in semi-thin section analysis of P28 sciatic nerve (Table I) was estimated by the proportion of axons in a 1:1 relationship with a Schwann cell that also contained myelin, as counted in three independent transverse sections.

Table I. Behavioral, Electrophysiological, and Morphological Phenotype Parallel Tg80 Copy Number and Expression

|            | Wild-type | Tg80.3 | Tg80.4 | Tg80.2 |
|------------|-----------|--------|--------|--------|
| Copy number| 0         | 2      | 14     | 31     |
| Fold overexpression*| 0 | 0.3 | 0.8 | 7.3 |
| Median life-span| >2 yr | >2 yr | 10 mo | 4 mo |
| Tremor     | ~         | ~      | +++    | ~      |
| Grip strength| 4.7 ± 0.28 (10) | 5.0 ± 0.06 (3) | 4.6 ± 0.20 (2) | 1.4 ± 0.14 (3) |
| Grip strength| 5.7 ± 0.30 (16) | 5.8 ± 0.45 (2) | 5.0 ± 0.01 (2) | 1.9 ± 0.15 (3) |
| NCV (m/s) | 36 ± 4.3 (5) | ND    | 11 ± 4.0 (4) | 2 ± 0.1 (3) |
| Percent myelinated fibers| 100 | 100 | 50 | <10 |

*Age of analyses: expression, tremor, and percent myelinated fibers at P28; grip strength at ~P100; NCV at P42.

1Absolute grip strength (g)/body weight (g).

2P < 0.01 by t test as compared with wild-type.

3The percent of axons in 1:1 relationships with Schwann cells that are myelinated.

Wrabetz et al. P2 Overexpression Causes Dysmyelination

1023
turer’s instructions. Equal amounts of homogenates (containing 2.5–10 μg of protein) were brought up to 5 μl with 9 M urea, to which was added 5 μl of 8 M urea, 0.05 M DTT, 1% SDS in water, followed by 10 μl of standard reducing sample buffer. The samples were denatured, resolved on a 12% SDS-polyacrylamide gel, and electroblotted onto PVDF membrane. Preliminary experiments with increasing amounts of wild-type nerve homogenates between 2.5 and 10 μg determined the linear range of dose-response for each of tubulin, MBP, PM22, and P0 to verify equal loading of protein; membranes were stained with amido black or ponceau red. Parallel blots were blocked with 0.05% Tween, 5% dry milk in PBS, and incubated with the appropriate antibody in 0.05% Tween and 1% dry milk in PBS. Mouse mAbs recognized P0 (P07, the generous gift of Dr. Juan A. Rachels, Department of Neurology, Karl-Franzens University, Graz, Austria; A. Rachels et al., 1993), MBP (Bioengineering Mannheim), PM22 (the generous gift of Dr. Ueli Suter, Swiss Federal Institute of Technology, Zürich, Switzerland), and β-tubulin (Sigma Chemical Co.). Peroxidase-conjugated secondary antibodies (Sigma Chemical Co.) were visualized using the ECL method with autoradiography film (Pharmacia Biotech). The intensity of bands was quantified by densitometry, and the ratio of intensities for each myelin protein and β-tubulin was determined. All bands were checked directly for equal loading by amido black staining after antibody experiments were completed. Deglycosylation with PNGase F and endoglycosidase H was performed on homogenates per manufacturer’s instructions (New England Biolabs). mAb P07 recognized two bands of Mm, 28,500 and 22,000-24,000, as previously noted in rodent nerve by A. Rachels et al. (1993), who speculated that the lower band was a degraded form of P0. Deglycosylation analysis of either transgenic or wild-type P28 nerve lysates showed that both bands contained a mixture of endoglycosidase H-sensitive and -resistant (immature and mature, respectively) forms of P0, as previously reported by Brunden (1992) for adult nerve.

Because both Northern and Western analysis of sciatic nerves pooled from ten Tg80.3 or ten normal littermates at P28 underestimated the decrease in MBP expression seen by Western analysis performed on pairs of nerves from single animals, we hypothesized that Tg80.3 animals manifested some combination of incomplete penetrance or variable expressivity for reduced MBP expression. Western blot analysis for P0 and MBP normalized to tubulin on multiple pairs of nerves confirmed incomplete penetrance, as 40% of Tg80.3 animals showed P0 overexpression as compared with the mean of the normal littermates, and each animal with P0 overexpression showed an ∼50% reduction of MBP (for example, see Fig. 9).

**Taqman® Quantitative RT-PCR Analysis**

Quantitative RT-PCR was performed as per manufacturer’s instructions (Taqman®; PE Applied Biosystems Instruments) on an A1 B1 PRISM 7700 sequence detection system (PE Applied Biosystems Instruments), using total RNA prepared as above from P28 sciatic nerves. The relative standard curve method was applied using total RNA from wild-type littermate sciatic nerves as the reference. Tg80.3 and wild-type determinations were carried out in separate tubes for both P0 mRNA and GAPDH mRNA. RT was performed as above; PCR amplification was performed with input RT product corresponding to 0.5 ng of starting RNA. PCR conditions were: 50°C for 2 min, 95°C for 10 min, followed by 95°C for 15 s, 60°C for 1 min for 40 cycles in TaqM® universal master reaction mix. Primers included: P0 forward, 5’-GGATGATGTTC-3’; P0 reverse, 5’-CAGCCTGAAGG-3’; and GAPDH forward, 5’-GGATGCAG-GGAAGATCT-3’; GAPDH reverse, 5’-GGATGCTTCAAGTGGGAGA-3’. Probes included: P0 FAM-5’-CTGGCATAGTGGAAAATCGAAA-3’; and GAPDH JOE-5’TAMRA. This analysis revealed that P0 mRNA was increased 0.68 ± 0.27 > 3 (mean ± SEM) in Tg80.3 relative to wild-type, which agrees reasonably well with 0.3-fold overexpression by semiquantitative RT-PCR analysis of the level of Tg80.3 mRNA relative to endogenous P0 mRNA, and 60% overexpression of P0 by Western analysis.

**Results**

**Extra Copies of Mpz Cause Dysmyelination in Peripheral Nerve**

To overexpress P0 we employed the mP0TOT transgene (Tg80), which contains the entire Mpz gene and 6 kb of 5’ flanking sequence (Fig. 1). mP0TOT containing the lacZ reporter gene embedded in Mpz exon 1 was previously shown to be expressed specifically in myelin-forming Schwann cells in postnatal peripheral nerve, in parallel with endogenous Mpz (Feltri et al., 1999). We prepared transgenic mice by standard techniques and obtained ten founders. Four manifested wobbling gait and tremor and were unable to breed. We were able to establish only one line from these severely affected mice by in vitro fertilization from the founder 80.2, and we subsequently maintained this line by ovarian transplantation. The remaining six founders manifested little or no tremor; two of these transmitted the transgene to progeny (hereafter, F80 denotes founder animals, whereas Tg80, animals of a line; e.g., F80.2 or Tg80.2). Southern blot analysis showed that copy number ranged from 1 to >40 (Fig. 1).

F80.1, F80.8, F80.9, and Tg80.2 animals (all copy number >20) showed a severe phenotype including gait difficulty, reduced weight, tremor, atrophy of the paraspinal and hindlimb musculature (Fig. 2A), and reduced lifespan (Table I). Nerve conduction velocities in the Tg80.2 animals were profoundly reduced to ∼2 m/s with temporal dispersion of the compound motor action potential (Fig. 2B) suggesting a dysmyelinating neuropathy. Morphological analysis of leg muscles showed angulated and atrophic fibers suggestive of denervation, but no fiber type group-
Morphological analysis of high copy number animals confirmed severe dysmyelination with rare evidence of myelin destruction. Semi-thin section analysis of P28 sciatic nerve from Tg80.2 animals showed remarkable hypomyelination and an increase in the number of Schwann cell nuclei (Fig. 3). Occasional patches of myelinated fibers were seen at P28 (Fig. 3) and more frequently at P42 (data not shown). Electron microscopic analysis of these nerves showed a mixture of fibers with thin myelin sheaths for the diameter of axon, and fibers in which single Schwann cells ensheathed axons, but formed no myelin (Fig. 4). Within the perineurial compartment, collagen was increased. There was little evidence of active demyelination as myelin debris was not seen extracellularly or in macrophages. Periodicity appeared normal in the few thin myelin sheaths present (Fig. 4, inset). Nonmyelin-forming (Remak) Schwann cells with apparently normal ensheathment and segregation of small axons could be found (Fig. 4). No axonal degeneration was observed.

Remarkably, in each transverse section of sciatic nerve at P28, several families of Schwann cells associated with bundles of naked axons of mixed caliber were identified (Fig. 3 C, arrows). Ultrastructural analysis (Fig. 4) revealed that nerve development was arrested at the stage in which Schwann cells were segregating large axons away from these bundles. Normally these bundles disappear from rodent sciatic nerve in the first few days after birth. Many other large axons were associated with, but only partially ensheathed by, a single Schwann cell surrounded by many pockets of redundant basal lamina containing collagen. Very rarely, single naked axons surrounded by a basal lamina were seen (data not shown). These data suggested that Schwann cells had incompletely retracted their processes after segregation of large axons. The unsorted bundles of axons did not depend on the site of chromosomal insertion of Tg80.2, as they were also present in F80.1 and F80.8, and very rarely in Tg80.4 animals. These features all suggested a perinatal effect of increased Mpz gene dosage.

Dysmyelination Results from Developmental Delay

To confirm that the defect in myelination resulted from developmental delay, and not myelin destruction, we examined nerves at various postnatal ages. In contrast to controls, Tg80.2 sciatic nerves at P5 and P14 contained virtually no myelin (Fig. 5). Also, the axon-sorting defect was more evident at P5 and P14 than at P28 by both semi-thin section analysis (compare Figs. 5 and 3) and EM (data not shown). Even in P45 or P90 transgenic nerves some bundles of unsorted larger diameter axons remained (Fig. 5). To quantitate the lack of myelin formation, we examined the motor branch (quadriiceps) of developing femoral nerve as previously described (Frei et al., 1999). By P10, 1% of axons in 1:1 relationships with Schwann cells were myelinated in Tg80.2 nerve, whereas virtually 100% of such axons were myelinated in wild-type nerve (Table II). A very low level of demyelination was detected in quadriiceps nerves, as occasional degenerating myelin fragments could be seen within axons or Schwann cells at P10. Thus, the abnormal features of P28 nerves resulted primarily from developmental delay, not from destruction of myelin that had been synthesized earlier, although some fibers acquired myelin by adulthood.

The occasional thinly myelinated fibers were not distributed randomly in transverse sections of sciatic nerve. One possibility was that motor and sensory fibers were differentially affected, since fibers originating from single spinal roots are also nonrandomly distributed in sciatic nerve (Ueyama, 1978). Consistent with this idea, the motor branch (quadriiceps) was more dysmyelinated than the sensory branch (saphenous) of femoral nerve by P10 in Tg80.2 animals (Table II). In addition, ventral roots were
more markedly dysmyelinated than dorsal roots in both Tg80.2 (Yin, X., unpublished results) and Tg80.3 homozygotes (see below; Quattrini, A., unpublished results). Thus, as in several other rodent models (reviewed in Martini, 1997), motor fibers are relatively more dysmyelinated than sensory fibers in Tg80 mice.

**Dysmyelination Parallels Mpz Dosage and Overexpression**

The increasing severity of the behavioral, electrophysiological, and morphological phenotype paralleled increasing transgene copy number (Table I; Fig. 6). For example, animals with 0–10 copies (Tg80.3, F80.10) appeared behaviorally normal, and had normally myelinated nerves by P28 (Fig. 6 B). In contrast, animals with 10–20 copies (Tg80.4 and F80.7) manifested mild tremor, NCV of 11m/s (Tg80.2), and dysmyelination with ~50% of the large axons ensheathed by single Schwann cells that had not formed myelin (Fig. 6 C). Finally, animals with >20 copies (Tg80.2, F80.1, F80.8, and F80.9) manifested evident tremor, weak grip strength, conduction velocity of 2 m/s (Tg80.2), and severe hypomyelination along with delayed axonal sorting (Fig. 6, E and F).

Thus, we performed RT-PCR analysis to confirm that the severity of phenotype paralleled Mpz overexpression. Primers that recognized exons 2 and 3 of Mpz, flanking a polymorphic restriction site in exon 3, allowed us to distinguish and quantitate the transgenic relative to endogenous P0 mRNA. We standardized the assay by analyzing mix-
tures of known amounts of cDNAs reverse-transcribed from sciatic nerve mRNA of BALB/c or FVB/N mice, the strains from which Tg80 or the endogenous \textit{Mpz} gene derived, respectively. As shown in Fig. 7B, the assay produced proportions within ±5% of the starting amounts. Analyzing mRNA from P28 sciatic nerves of Tg80.2, Tg80.3, or Tg80.4 animals, we found that \textit{Mpz} was overexpressed from 30 to ~700%. Overexpression paralleled copy number, and severity of phenotype, among the categories of low, medium, and high copy number (Table I).

To show that \textit{Mpz} was overexpressed shortly after birth, the point in development at which myelination was delayed, we performed RT-PCR analysis on Tg80.2 sciatic nerves at P2. We found that the ratio of Tg80 to endogenous \textit{Mpz} was 6.9-fold at P2, very similar to 7.3-fold determined at P28 (Fig. 7 C). This data, taken together with the demonstration by ultrastructural immunocytochemistry that \textit{P0} is significantly increased in periaxonal, abaxonal, and Golgi membranes of arrested Tg80.2 Schwann cells at P5 (see Figure 3 of Yin et al., 2000, this issue), shows that \textit{P0} overexpression is associated with congenital hypomyelination in sciatic nerve.

In the mildly affected Tg80.3, dysmyelination was related to the expression of endogenous \textit{Mpz}. As \textit{Mpz} expression approaches its peak between P15 and P21 (Stahl et al., 1990), Tg80.3 sciatic nerves were hypomyelinated (thin sheaths for axon diameter) as compared with control (data not shown), whereas by P28, when \textit{Mpz} expression is falling to adult levels, sciatic nerves contained ultrastructurally normal myelin (Fig. 6 B). Thus, we hypothesized that total \textit{Mpz} expression in Tg80.3 sciatic nerves had exceeded a threshold at P15, above which hypomyelination results. To directly identify such a threshold, we bred Tg80.3 to homozygosity. P28 Tg80.3 homozygotes manifested tremor and dysmyelination (Fig. 6 D), whereas P28 Tg80.3 hemizygotes did not (Fig. 6 B). RT-PCR analysis confirmed an increase in overexpression from 30% in Tg80.3...
As compared with Tg80.4 (Fig. 8 B), Tg80.4 in the heterozygous null background produced more myelin in sciatic nerve, showing a mixture of hyper- and hypomyelinated fibers (Fig. 8 F). When Tg80.4 was bred into the homozygous null background, myelination returned to essentially normal (Fig. 8 D), consistent with the prediction that total P0 expression should decrease from 180% in Tg80.4 animals to near normal in Tg80.4/homozygous Mpz null animals. These data demonstrate that a threshold exists for Mpz overexpression between 30 and 80% (130–180% total Mpz expression), above which dysmyelination results. More importantly, in the absence of endogenous Mpz, Tg80.4 generated P0 sufficient to form normal myelin sheaths. Therefore, the overexpression phenotype depends uniquely on dosage of Mpz, not on an ectopic effect or structural alteration of transgenic P0.

P0 Glycoprotein Is Overexpressed

To determine whether increased dosage of Mpz and expression of P0 mRNA resulted in overexpression of P0, we performed Western blot analysis. In Tg80.3 nerves at P28, where nerves were ultrastructurally normal (Fig. 6 B), P0 was overexpressed by ~60% (Fig. 9; 0.6 ± 0.16, n = 5 [mean ± SEM]), as predicted by the RT-PCR analysis. Increased total P0 mRNA was sufficient to explain this increase, as confirmed by Taqman® quantitative RT-PCR analysis: total P0 mRNA in Tg80.3 sciatic nerves was increased 0.68 ± 0.27, n = 3. Of note, as Mpz overexpression rose further, the level of P0 fell, corresponding to more severe dysmyelination: it was slightly less than control in Tg80.4, and significantly reduced in Tg80.2. Thus, as P0 overexpression exceeds a threshold leading to dysmyelination, mRNA and protein levels diverge, as protein levels reflect primarily the bulk quantity of P0 in myelin sheaths. P0 deriving from the transgene could not be distinguished from endogenous P0 (including deglycosylation with PNGase F or endoglycosidase H, followed by Western blot analysis, data not shown) suggesting that the transgenic protein underwent normal posttranslational modification. In keeping with this, ultrastructural immunocytochemical analysis showed that the few myelin sheaths seen in P42 Tg80.2 ventral roots contained 40% more grains for P0 as compared with control sheaths (see Figure 4 of Yin et al., 2000, this issue). Thus, at least some of the extra P0 probably arrived to myelin sheaths.

P0 Overexpression Is Accompanied by Dysregulated Expression of Other Myelin Genes, even in the Absence of Dysmyelination

To examine for possible effects of P0 overexpression on the synthesis of other myelin proteins in the presence of normal myelination or dysmyelination, we performed Western blot analysis on P28 sciatic nerves from animals of low (Tg80.3), medium (Tg80.4), or high (Tg80.2) copy number. As for P0, the level of MBP was reduced in association with the loss of bulk myelin in Tg80.4 and Tg80.2 nerves. In addition, higher molecular weight isoforms of MBP, which in the CNS are associated with early myelinogenesis (Barbarese et al., 1978), were predominant in Tg80.4 and Tg80.2, consistent with developmental delay, whereas the 18-kD isoform, most abundant in mature CNS myelin

hemizygote nerves to 80% in Tg80.3 homozygote nerves (Fig. 7 C). Of note, the effects of Mpz overexpression were reproducible between transgenic lines, as the behavioral and morphologic phenotypes of Tg80.3 homozygotes (80% overexpression) and Tg80.4 animals (80% overexpression) were similar (compare Fig. 6, C and D). These data confirm that the severity of dysmyelination depends on Mpz dosage.

To further confirm this relationship, and that dysmyelination did not depend on ectopic expression or a structural alteration of Tg80, the reverse experiment was performed by breeding Tg80.4 into the Mpz null background.
sheaths, was predominant in Tg80.3 and the control. Surprisingly, the MBP level was reduced by 50% in P28 Tg80.3 sciatic nerves as compared with control (Fig. 9; 0.52 ± 0.05, n = 5), in the absence of myelin abnormality (Fig. 6 B). PMP22 was also reduced by 35% in Tg80.3 (0.37 ± 0.16, n = 2), but was equal to, or twofold increased in Tg80.2 and Tg80.4 nerves, respectively (Fig. 9). The level of a nonmyelin protein, tubulin, was not altered. P0 overexpression thus perturbed myelin protein levels in not only the presence, but also the absence of dysmyelination, where the reduced levels of proteins cannot be explained by the loss of bulk myelin.

Since P0 accounts for >50% of protein in peripheral myelin (Greenfield et al., 1973), and thus represents the bulk of protein in nerve lysates, overexpression of P0 might artificially cause a reduction in the amount of other proteins detected in Western blots. For instance, overexpression of P0 by 60% might be expected to increase total nerve protein by ~30%, and if the expression of other proteins remains unchanged, their proportion of total nerve protein would be reduced by 25%. To control for this possibility, amido black staining of blots revealed that proteins other than P0 or MBP (easily recognized in amido black staining, see Fig. 9) were equally loaded between Tg80.3 and control (Fig. 9). Moreover, the reduction in MBP was 50%, significantly >25%, and therefore, out of proportion to changes in total protein due to P0 overexpression. Thus, Schwann cells sense and respond to P0 overexpression by dysregulating other myelin proteins before exceeding a threshold for dysmyelination.

Discussion

We have shown that myelogenesis requires expression of the P0 within a narrowly defined range. Our data are most consistent with a model in which overexpressing P0 results in dose-dependent arrest of nerve development, ranging from transient hypomyelination with mild overexpression, to arrest of Schwann cells in a 1:1 relationship with large axons with moderate overexpression, to inability of Schwann cells to segregate axons with the highest overexpression. This array of phenotypes suggests multiple pathogenetic mechanisms, some acting before and some during myelin formation. We have identified two plausible mechanisms: the first involves altered trafficking of P0 in promyelin-forming Schwann cells (Y in et al., 2000, this issue), and the second involves abnormal stoichiometry in the expression of myelin genes. These studies reveal new stages in nerve development at which Schwann cells are susceptible to altered gene dosage and suggest that P0 overexpression represents a new mechanism of hereditary neuropathy.
The phenotypes observed in \( P_0 \) transgenic mice do not arise from structural alteration or ectopic expression of the transgenic protein. First, a version of \( mP_0TOT \) containing \( \alpha\text{C}1\beta\text{C1} \) embedded in exon 1 expressed the reporter with the same cell-specific and developmental profile as \( \text{Mpz} \) (Feltri et al., 1999). Moreover, in the present study, the ratio of transgenic to endogenous \( P_0 \) mRNA remained stable from P2 to adulthood (Wrabetz, L., unpublished result). Second, Western blot analysis of multiple independent lines revealed that the transgenic and endogenous \( P_0 \) proteins were indistinguishable, even by deglycosylation analysis. Most importantly, when the \( P_0 \) transgene (\( Tg80.4 \) line) was bred into the homozygous \( P_0 \) null background, normal myelination resulted, even though all \( P_0 \) was transgenic in origin. The sum of this data strongly supports the view that the phenotype of \( P_0 \) transgensics derives from increased dosage and expression of \( \text{Mpz} \) in Schwann cells.

**Schwann Cell Response to \( P_0 \) Overexpression Is Specific**

Dysmyelination might represent a nonspecific response to glycoprotein overexpression. However, even though Schwann cell development is arrested by altered dosage of several genes related to myelination (some encoding glycoproteins), specific morphological features distinguish each phenotype (\( \text{Mpz} \), Giese et al., 1992; \( \text{MbP}22 \), A. Diklofer et al., 1995; M. Aygar et al., 1996; Sereda et al., 1996; H. Uxley et al., 1998; O. Cito, B. Bermingham et al., 1996; J. Aagle et al., 1996; K. Roxo, T. Popilko et al., 1994). In particular, developmental arrest at the stage of sorting large caliber axons from bundles of naked axons is unique to \( P_0 \) overexpression, suggesting an effect early in nerve development. The data from Yin et al. (2000, this issue) demonstrate that even common morphological features belies specific Schwann cell dysfunction. Schwann cells arrested in a 1:1 relationship with axons in \( P_0 \) transgenic mice have narrowed mesaxonal spaces, whereas the same cells in \( \text{PMP22} \) overexpressor mice do not (compare Figure 6 in Y in et al., 2000, this issue, to Figure 7 in Huxley et al., 1998). Finally, we report that misrouting of \( P_0 \) in the \( P_0 \) transgenic mice does not disrupt sorting of myelin-associated glycoprotein into appropriate subcellular compartments (Y in et al., 2000, this issue), indicating that glycoprotein trafficking is not generally impaired.

**Dose Dependence and Mechanisms of Developmental Arrest**

The phenotype resulting from \( P_0 \) overexpression is dose-dependent. A single copy number and the level of transgenic mRNA rise, the behavioral and electrophysiological phenotype worsen, and the proportion of appropriately myelinated fibers falls (Fig. 6; Table I). Breeding the \( Tg80.3 \) line (30% overexpression) to homozygosity produced dysmyelination similar to hemizygous \( Tg80.4 \) mice with comparable levels of expression (Fig. 7 C). Conversely, crossing the \( Tg80.4 \) transgene into the homozygous \( P_0 \) null background (predicted normalized \( P_0 \) levels) produced normal myelination (Fig. 8). These experiments place the threshold for dysmyelination between 30 and 80% \( P_0 \) overexpression. It is important to note that the phenotype of \( P_0 \) overexpression is one of dysmyelination, not demyelination. Study of early development in \( Tg80.4 \) (not shown) and \( Tg80.2 \) mice (Fig. 5) demonstrates that myelin is never properly formed in affected fibers, not that myelin is formed and then destroyed.

As a general rule, as \( \text{Mpz} \) dosage rises, Schwann cells are progressively impaired. Thus, we observed three categories of abnormal Schwann cells in \( P_0 \) overexpression nerves: 1, Schwann cells that formed thin myelin; 2, Schwann cells arrested after having ensheathed a large axon and advanced a mesaxon; and 3, Schwann cells arrested as they attempted to sort axons. Nerves with low \( P_0 \) overexpression (e.g., \( Tg80.3 \)) have only the first type of Schwann cells; nerves with moderate overexpression (e.g., \( Tg80.4 \)) have primarily the first and second type of Schwann cells; nerves with highest overexpression (e.g., \( Tg80.2 \)) have all three types.

It is important to note that our quantitation of \( P_0 \) overexpression is at the level of whole nerve, whereas the heterogeneity of phenotypes in individual cells suggests variation in either the level of transgene expression or susceptibility to dysmyelination. Interestingly, we observed that motor nerves and ventral roots were more severely affected than sensory nerves and dorsal roots in the \( P_0 \) transgensics. In fact, semiquantitative in situ hybridization analysis for \( P_0 \) mRNA on teased fibers from sciatic nerves shows that Schwann cells associated with larger fibers express more \( P_0 \) (Griffiths et al., 1989). Perhaps motor fibers, which are larger than sensory fibers on the average, have a stronger stimulus to express both endogenous and transgenic \( P_0 \), and therefore more quickly achieve levels of \( P_0 \) overexpression sufficient to arrest Schwann cell development. Similarly increased susceptibility of Schwann cells associated with motor axons to dysmyelination has been observed with mutations or dosage alterations of \( \text{PMP22} \), \( \text{Mpz} \), \( \text{Mag} \), and \( \text{Cx32} \) (Martini, 1997).

More than one mechanism may account for these Schwann cell abnormalities in \( P_0 \) overexpressor nerves.
For example, nerves of the Tg80.3 line at P28, with ultrastructurally normal myelin, manifest a 50% increase of P₀ protein in combination with reduced levels of two other myelin proteins, MBP and PMP22. Preliminary analysis suggests that these alterations are reflected in part by changes in mRNA levels (Wrabetz, L., and M.L. Feltri, unpublished observation). We propose that the Schwann cell response to P₀ overexpression further dysregulates the stoichiometry of myelin proteins (MBP and PMP22 are required for normal peripheral nerve myelination; A D’Urso et al., 1995; Gould et al., 1995; Martini et al., 1995), leading to reversible hypomyelination at the peak of P₀ gene expression in the third week after birth, and recovery as P₀ expression falls to adult levels. Parallel morphological and expression analysis throughout Tg80.3 nerve development will be required to test this hypothesis.

In contrast, the Schwann cells that are arrested at the stage of 1:1 relationships with axons deliver P₀ to atypical membrane locations. In Y in et al. (2000, this issue), we show that mistargeting of P₀ to the membranes of the advancing mesaxon activates obligate P₀ homophilic adhesion, arresting spiral wrapping and myelination.

Finally, many Schwann cells in the severely affected mice are unable to properly sort mixed caliber axons in spinal roots and nerves. P₀ was detected in these Schwann cells by immunocytochemistry (Yin et al., 2000, this issue). This sorting defect likely arises from P₀ overexpression rather than ectopic expression, as both P₀ mRNA and protein also have been detected in normal late embryonic nerves, when Schwann cell sorting of axons normally begins (Lee et al., 1997). Qualitative analysis of Schwann cell number (Fig. 3) and internuclear distance (Yin et al., 2000, this issue) in the severely affected nerves suggest that there is no defect in Schwann cell proliferation or survival, a conclusion that is also supported by BrdU-labeling indices (Yin, X., and B.D. Trapp, unpublished observation). This is in contrast to ErbB3-null mice, in which sciatic nerves contain bundles of unsorted axons due to a marked reduction in the number of Schwann cells (Riemhacker et al., 1997). Alternatively, as an adhesion molecule, P₀ may interfere with Schwann cell migration or elongation. In dystrophic (dy/dy) mice with laminin 2 deficiency, spinal nerves also contain bundles of naked, mixed caliber axons, hypothesized to be due to a Schwann cell migration defect (Maddir et al., 1975). Further studies of the cell growth and the molecular phenotype of the P₀ transgenic Schwann cells are underway to distinguish these possibilities.

### P₀ Gene Dosage and Stoichiometry

Mutations in both P₀ and PM22 result in similar dysmyelinating phenotypes, suggesting common functions. Recently, D’Ursu et al. (1999) have provided biochemical evidence for physical interaction between P₀ and PM22, suggesting the possibility of multiprotein assemblies in myelin. Determination of the crystal structure of the P₀ extracellular domain suggests that P₀ could interact with itself in compact myelin to form a planar crystal with regular spaces (Shapiro et al., 1996). Such structures could potentially accommodate PM22 (D’Ursu et al., 1999) and define a fixed ratio between P₀ and PM22 content. As noted above, the threshold of overexpression (80%) is remarkably similar for both P₀ (present study) and PM22 (Huxley et al., 1998), a result that could be interpreted in terms of a fixed stoichiometry in their assembly. One prediction of such a model is that overexpression of one partner protein may perturb assembly through trans-dominant negative interactions with the other (e.g., sequestration or altering geometric interactions). Paradoxically, therefore, matching of the expression of partner proteins to comply with stoichiometric requirements may rescue dysmyelination, for example by crossing appropriate P₀ and PM22-overexpressing mice. Such paradoxical rescue has been observed in CNS myelin when the shiverer phenotype (absence of MBP) was improved by reducing PLP dosage (Stoffel et al., 1997).

### Implications for Hereditary Neuropathies

Increased dosage of PM22 and PLP causes both rodent and human myelinopathies (CMT1A and Pelizaeus-Merzbacher disease, respectively), and 80% overexpression of MPZ causes neuropathy in mice. Could altered dosage of MPZ cause human neuropathy? Partial trisomies of human chromosome 1 that include the MPZ locus 1q22 are rare and produce complex phenotypes; one such case included equinovarus alterations of the feet and contractures of the extremities, which suggest, but do not prove, peripheral neuropathy (Chen et al., 1994). Also, P₀ mis-sense mutations are associated with the human demyelinating neuropathies CMT1B, Déjérine Sottas syndrome, and congenital hypomyelination neuropathy (CHN; Warner et al., 1996). Of note, profoundly reduced nerve conduction velocities (1–2 m/s), the paucity of active myelin destruction or onion bulbs, and the redundant basement membrane formation (Fig. 4 C) in P₀ overexpressor mice resemble CHN (Harati and Butler, 1985). In addition, low level P₀ overexpression produces transient hypomyelination in mice, similar to a subset of reversible CHN (Ghamdi et al., 1997; Levy et al., 1997). Finally, mutations in the Krox 20 transcription factor, encoded by EGR2, are also associated with CHN. Since one of these EGR2 mutations likely disinhibits Krox 20 (Warner et al., 1998), and Krox 20 may regulate P₀ expression (Topilko et al., 1994; Zorick et al., 1999), it is possible that MPZ overexpression contributes to the pathogenesis of this EGR2 mutation.

The present study advises caution for treatment of CMT1B neuropathies in which the MPZ mutation predicts loss of P₀ expression, and for which replacement gene therapy might therefore be considered (Shy et al., 1995; Guenard et al., 1999). Such therapy may require exceptionally precise regulation of P₀ expression in human nerve, as only 60% overexpression in mice results in impaired myelin formation.

Finally, Tg80.2 animals develop atrophy and morphologic changes in skeletal muscle, and a trend towards reduced nerve action potential amplitude, that together suggest axonal pathology. Axonal degeneration was not observed in studies of proximal nerves or lumbar ventral roots, but is prominent in intramuscular nerve branches (Yin, X., and B.D. Trapp, unpublished observations). It is well established from mouse models that primary defects in Schwann cells can lead to secondary changes in axonal properties (de Waegh et al., 1992; Yin et al., 1998), includ-
ing in distal nerves where axons might even be prone to degenerate (Frei et al., 1999; Sancho et al., 1999). Similarly, hereditary demyelinating neuropathies in man manifest important axonal effects, more prominent distally, which account for significant disability. Thus, mice overexpressing P0 may provide another useful model for studying the pathogenesis of axonal damage as a consequence of a primary Schwann cell dysfunction.

We thank Marta A. Arona, Marina Fasolini, H. Heide Peickert, Rita Numerato, and D. enience Springer for expert technical assistance; Professor Mellett Schachner for the generous gift of P0 null mice; Drs. Juan Archelos and Ueli Suter for the generous gifts of antibodies; and Professors Edoardo Boccelli and Nicola Can for support.

This study was supported by grants from Telethon, Italy (#1177 to L. Wrabetz, #093 to M. L. Feltri); European Community Biomed Program (#MH-CT-97-2099 to L. Wrabetz); Fondazione Giovanni A: rneise-H arvard (L. Wrabetz and M. L. Feltri); and NIH (NS-23375 to S.Y. Chiu and A. Messing, and NS-38186 to B.D. Trapp).

Submitted: 19 October 1999
R: Revised: 13 January 2000
A: Accepted: 24 January 2000

References

http://www.jcb.org/cgi/content/abstract/148/6/1032

A dikofer, K., R. Martini, A. A. gujzi, J. Zielasek, K.V. Toyka, and U. Suter. 1995. Hypermyelination and demyelinating peripheral neuropathy in Pmp22-deficient mice. Nat. Genet. 11:274–280.
Archelos, J.J., J. Schneider-Schaulies, C. Linington, K.V. Toyka, and H.P. Hartung. 1993. Production and characterization of monoclonal antibodies to the extracellular domain of P0. J. Neurosci. Res. 35:46–53.
Barbarese, E., J.H. Carson, and P. Braun. 1978. Accumulation of the four myelin basic proteins in mouse brain during development. J. Neurosci. 31:779–782.
Bemsingman, J.R., J.R., S.S. Scherer, S. O’Connell, E. Arroyo, K.A. Kalla, F.L. Powell, and M.G. Rosenfeld. 1996. Tnt-tO ct-65 ICIP regulates a unique step in peripheral myelination and is required for normal respiration. Genes Dev. 10:1751–1762.
Boisfont, D., and W. Stoffel. 1994. Disruption of the compacted myelin sheath of axons of the central nervous system in proteolipid protein-deficient mice. Proc. Natl. Acad. Sci. USA 91:11709–11713.
Birnster, R.L., Y. Chen, M.E. Trumbauer, M.K. Yagle, and R.D. Palmeter. 1985. Factors affecting the efficiency of introducing foreign DNA into mice by microinjecting eggs. Proc. Natl. Acad. Sci. USA 82:4438–4442.
Budden, K.R. 1992. A gene-dependent changes in the oligosaccharide structure of the major myelin glycoprotein, P0. J. Neurochem. 58:1659–1666.
Chen, H., C.J. Kusky, C.M. Tuck-Muller, J.E. Martine, R.D. D’orand, and W. Wertelecki. 1994. Confirmation of proximal 1q duplication using fluorescent in situ hybridization. Am. J. Med. Genet. 50:28–31.
Chinni, J.M., A.E. Fryzyla, R.J. MacDonald, and R.J. Rutter. 1979. Isolation of biologically active ribonuclease acid from mouse RNA in ribonuclease. Biochemistry. 18:5292–5299.
Colman, D.R., G. Kreibel, A.B. Frey, and D.D. Sabatini. 1982. Synthesis and incorporation of myelin polypeptides into CNS myelin. J. Cell Biol. 95:598–608.
Dos Rr, D.P., J.R. Branch, S.M. Staugaitis, C.S. Gilless, A.B. Frey, J.G. Stemp, and D.R. Colman. 1990. Protein zero of peripheral nerve myelin: biochemistry, membrane insertion, and evidence for homotypic interaction. Neuron. 4:449–460.
Dos Rr, D.P., E. Ehrhardt, and H.W. Muller. 1999. Peripheral myelin protein 22 and protein zero: a novel association in peripheral nervous system myelin. J. Neurosci. 19:3396–3403.
De Waegh, S.M., V.M. Lee, and S.T. Brady. 1992. Localization of myofibril phosphorylation, axonal caliber, and slow axonal transport by myelinating Schwann cells. Cell. 68:451–456.
Felti, M.L., M.A. Antonio, A. Quattrini, R. Numerato, M. A. Rona, S. Prevaliti, S.Y. Chiu, A. Messing, and L. Wrabetz. 1999. A novel P0 glycoprotein transgene activates expression of la2 in myelinating Schwann cells. Eur. J. Neurosci. 11:1577–1586.
Fibis, M.T., F.S. Walsh, B.D. Trapp, J.A. Fizzy, and G.J. Tenkeko. 1990. Role of myelin P0 protein as a homophilic adhesion molecule. Nature 344:871–872.
Frei, R., S. Mooting, I. Kinkelr, M. Schachner, M. Koltenburg, and R. Martin. 1999. Loss of distal axons and sensory M. erkel cells and features indicative of muscle denervation in hindlimbs of P0-deficient mice. J. Neurosci. 19:6058–6067.
Ghami, M., D.L. A mstron, and G. Miller. 1997. Congenital hypomyelinating neuropathy: a reversible case. Pediatr. Neurol. 16:71–73.
Giese, K.P., R. Martini, G. Lenke, P. Soriano, and M. Schachner. 1992. Mouse
tural protein of peripheral nerve myelin. Neuron. 17:435–449.
Shy, M.E., M. Tani, Y.J. Shi, S.A. Whyatt, T. Chbihi, S.S. Scherer, and J. Kamholz. 1995. A nonadenoviral vector can transfer lacZ expression into Schwann cells in culture and in sciatic nerve. Ann. Neurol. 38:429–436.
Stahl, N., J. Harry, and B. Popko. 1990. Quantitative analysis of myelin protein gene expression during development in the rat sciatic nerve. Mol. Brain Res. 8:209–212.
Stoffel, W., D. Boison, and H. Bussow. 1997. Functional analysis in vivo of the double mutant mouse deficient in both proteolipid protein (PLP) and myelin basic protein (MBP) in the central nervous system. Cell Tissue Res. 289:195–206.
Suter, U., and G.J. Snipes. 1995. Biology and genetics of hereditary motor and sensory neuropathies. Annu. Rev. Neurosci. 18:45–75.
Topilko, P., S. Schneider-Maunoury, G. Levi, A. Baron-Van Evercooren, A.B. Chennoufi, T. Seitandou, C. Babinet, and P. Charnay. 1994. Krox-20 controls myelination in the peripheral nervous system. Nature. 371:796–799.
Trapp, B.D., T. Moench, E. Barbosa, G. Tennekoon, and J. Griffin. 1987. Spatial segregation of mRNA encoding myelin-specific proteins. Proc. Natl. Acad. Sci. USA. 84:7773–7777.
Trapp, B.D., G.J. Kidd, P. Hauer, E. Mulrenin, C.A. Haney, and S.B. Andrews. 1995. Polarization of myelinating Schwann cell surface membranes: role of microtubules and the trans-Golgi network. J. Neurosci. 15:1797–1807.
Ueyama, T. 1978. The topography of root fibres within the sciatic nerve trunk of the dog. J. Anat. 127:277–290.
Vallat, J.M., P. Sindou, P.M. Preux, F. Tabaraud, A.M. Milor, P. Couratier, E. LeGuern, and A. Brice. 1996. Ultrastructural PM P22 expression in inherited demyelinating neuropathies. Ann. Neurol. 39:813–817.
Warner, L.E., M.J. Hilz, S.H. Appel, J.M. Killian, E.H. Kolodny, G. Karpati, S. Carpenter, G.V. Watters, C. Wheeler, D. Witt, et al. 1996. Clinical phenotypes of different MPZ (P0) mutations may include Charcot-Marie-Tooth Type 1b, Dejerine-Sottas, and congenital hypomyelination. Neuron. 17:451–460.
Warner, L.E., P. Mancias, I.J. Butler, C.M. McDonald, L. Keppen, K.G. Koob, and J.R. Lupski. 1998. Mutations in the early growth response 2 (EGR2) gene are associated with hereditary myelopathies. Nat. Genet. 18:382–384.
Warner, H., M. Jung, M. Klugmann, M. Sereda, I.R. Griffiths, and K.A. Nave. 1998. Mouse models of myelin diseases. Brain Pathol. 8:771–793.
Wrabetz, L., C. Taverggia, M. Feltri, A. Quattrini, R. A watramani, S. Scherer, A. Messing, and J. Kamholz. 1998. A minimal human MBP promoter-lacZ transgene is appropriately regulated in developing brain and after optic neuritis, but not in shiverer mutant mice. J. Neurobiol. 34:10–26.
Yin, X., T.O. Crawford, J.W. Griffin, P. Tu, V.M. Lee, C. Li, J. Roder, and B.D. Trapp. 1998. Myelin-associated glycoprotein is a myelin signal that modulates the caliber of myelinated axons. J. Neurosci. 18:1953–1962.
Yin, X., G. Kidd, L. Wrabetz, M. Feltri, A. Messing, and B. Trapp. 2000. Schwann cell myelination requires timely and precise targeting of P0 protein. J. Cell Biol. 148:1009–1020.
Zorick, T.S., D.E. Syroid, A. Brown, T. Gridley, and G. Lemke. 1999. Krox-20 controls SCP expression, cell cycle exit and susceptibility to apoptosis in developing myelinating Schwann cells. Development. 126:1397–1406.